S Ezzat

Summary

Affiliation: Mount Sinai Hospital
Country: Canada

Publications

  1. ncbi request reprint A soluble dominant negative fibroblast growth factor receptor 4 isoform in human MCF-7 breast cancer cells
    S Ezzat
    Department of Medicine, University of Toronto, 600 University Avenue, Toronto, Ontario, Canada M5G 1X5
    Biochem Biophys Res Commun 287:60-5. 2001
  2. ncbi request reprint Pituitary tumor-derived fibroblast growth factor receptor 4 isoform disrupts neural cell-adhesion molecule/N-cadherin signaling to diminish cell adhesiveness: a mechanism underlying pituitary neoplasia
    Shereen Ezzat
    Department of Medicine, University of Toronto, Canada
    Mol Endocrinol 18:2543-52. 2004
  3. ncbi request reprint The prevalence of pituitary adenomas: a systematic review
    Shereen Ezzat
    Department of Medicine, University of Toronto and Mount Sinai Hospital, Toronto, Ontario, Canada
    Cancer 101:613-9. 2004
  4. pmc Decision aid on radioactive iodine treatment for early stage papillary thyroid cancer--a randomized controlled trial
    Anna M Sawka
    Division of Endocrinology, Department of Medicine, University Health Network and University of Toronto, Toronto, Ontario, Canada
    Trials 11:81. 2010
  5. pmc The molecular pathogenetic role of cell adhesion in endocrine neoplasia
    S Ezzat
    Department of Medicine, University of Toronto, Endocrine Oncology Site Group, Mount Sinai and Princess Margaret Hospitals, Ontario Cancer Institute, University Health Network, Toronto, Ontario, Canada M5G 1X5
    J Clin Pathol 58:1121-5. 2005
  6. ncbi request reprint A Canadian multi-centre, open-label long-term study of Pegvisomant treatment in refractory acromegaly
    Shereen Ezzat
    University of Toronto, Mount Sinai Hospital, Toronto, ON, M5G 1X5
    Clin Invest Med 32:E265. 2009
  7. ncbi request reprint The role of hormones, growth factors and their receptors in pituitary tumorigenesis
    S Ezzat
    Department of Medicine, University of Toronto, and The Freeman Centre for Endocrine Oncology, Mount Sinai Hospital, Ontario, Canada
    Brain Pathol 11:356-70. 2001
  8. ncbi request reprint Canadian consensus guidelines for the diagnosis and management of acromegaly
    Shereen Ezzat
    University of Toronto, Toronto, Ontario
    Clin Invest Med 29:29-39. 2006
  9. ncbi request reprint Pharmacological approach to the treatment of acromegaly
    Shereen Ezzat
    Division of Endocrinology and Metabolism, University of Toronto, Ontario, Canada
    Neurosurg Focus 16:E3. 2004
  10. ncbi request reprint FGF receptor signaling at the crossroads of endocrine homeostasis and tumorigenesis
    S Ezzat
    Department of Medicine, University of Toronto, Endocrine Oncology Site Group, Mount Sinai and Princess Margaret Hospitals, Ontario Cancer Institute, University Health Network, Toronto, Ontario, Canada
    Horm Metab Res 37:355-60. 2005

Collaborators

Detail Information

Publications85

  1. ncbi request reprint A soluble dominant negative fibroblast growth factor receptor 4 isoform in human MCF-7 breast cancer cells
    S Ezzat
    Department of Medicine, University of Toronto, 600 University Avenue, Toronto, Ontario, Canada M5G 1X5
    Biochem Biophys Res Commun 287:60-5. 2001
    ..These findings represent the first description of an endogenous soluble C-terminally truncated FGFR4 isoform with FGF modulatory properties...
  2. ncbi request reprint Pituitary tumor-derived fibroblast growth factor receptor 4 isoform disrupts neural cell-adhesion molecule/N-cadherin signaling to diminish cell adhesiveness: a mechanism underlying pituitary neoplasia
    Shereen Ezzat
    Department of Medicine, University of Toronto, Canada
    Mol Endocrinol 18:2543-52. 2004
    ....
  3. ncbi request reprint The prevalence of pituitary adenomas: a systematic review
    Shereen Ezzat
    Department of Medicine, University of Toronto and Mount Sinai Hospital, Toronto, Ontario, Canada
    Cancer 101:613-9. 2004
    ..With these additional classifications in mind, the goals of the current study were to determine the prevalence of pituitary adenomas and to explore the clinical relevance of the findings...
  4. pmc Decision aid on radioactive iodine treatment for early stage papillary thyroid cancer--a randomized controlled trial
    Anna M Sawka
    Division of Endocrinology, Department of Medicine, University Health Network and University of Toronto, Toronto, Ontario, Canada
    Trials 11:81. 2010
    ..This decision is often difficult because of conflicting reports of RAI treatment benefit and medical evidence uncertainty due to the lack of long-term randomized controlled trials...
  5. pmc The molecular pathogenetic role of cell adhesion in endocrine neoplasia
    S Ezzat
    Department of Medicine, University of Toronto, Endocrine Oncology Site Group, Mount Sinai and Princess Margaret Hospitals, Ontario Cancer Institute, University Health Network, Toronto, Ontario, Canada M5G 1X5
    J Clin Pathol 58:1121-5. 2005
    ..Validation of the functional relevance of these adhesive pathways will be discussed in light of targeted pharmacotherapeutic studies that are unmasking novel approaches to the treatment of neuroendocrine tumours...
  6. ncbi request reprint A Canadian multi-centre, open-label long-term study of Pegvisomant treatment in refractory acromegaly
    Shereen Ezzat
    University of Toronto, Mount Sinai Hospital, Toronto, ON, M5G 1X5
    Clin Invest Med 32:E265. 2009
    ..Here we report the results of a Canadian multi-centre study open-label, dose-titrated long-term study examining safety and efficacy outcomes of a growth hormone receptor antagonist, pegvisomant in 19 patients with refractory acromegaly...
  7. ncbi request reprint The role of hormones, growth factors and their receptors in pituitary tumorigenesis
    S Ezzat
    Department of Medicine, University of Toronto, and The Freeman Centre for Endocrine Oncology, Mount Sinai Hospital, Ontario, Canada
    Brain Pathol 11:356-70. 2001
    ....
  8. ncbi request reprint Canadian consensus guidelines for the diagnosis and management of acromegaly
    Shereen Ezzat
    University of Toronto, Toronto, Ontario
    Clin Invest Med 29:29-39. 2006
    ..This paper summarizes the working group's findings and the points of consensus that were achieved...
  9. ncbi request reprint Pharmacological approach to the treatment of acromegaly
    Shereen Ezzat
    Division of Endocrinology and Metabolism, University of Toronto, Ontario, Canada
    Neurosurg Focus 16:E3. 2004
    ..This last line of therapy should be considered for use in patients in whom surgery and medical therapy with somatostatin and/or dopamine agonists are either ineffective or poorly tolerated...
  10. ncbi request reprint FGF receptor signaling at the crossroads of endocrine homeostasis and tumorigenesis
    S Ezzat
    Department of Medicine, University of Toronto, Endocrine Oncology Site Group, Mount Sinai and Princess Margaret Hospitals, Ontario Cancer Institute, University Health Network, Toronto, Ontario, Canada
    Horm Metab Res 37:355-60. 2005
    ..This review will examine the evidence that FGF/FGFRs play a role in sporadic endocrine neoplasia and the pathways in which these molecules may be selectively targeted for therapeutic purposes...
  11. ncbi request reprint Pharmacological options in the treatment of acromegaly
    Shereen Ezzat
    Mount Sinai Hospital, University of Toronto, Canada
    Curr Opin Investig Drugs 6:1023-7. 2005
    ..This review will summarize the current major classes of pharmacotherapeutic agents with special emphasis on their recognized benefits and risks...
  12. pmc Thyroid cancer patients' involvement in adjuvant radioactive iodine treatment decision-making and decision regret: an exploratory study
    A M Sawka
    Division of Endocrinology, Department of Medicine, University Health Network Toronto General Hospital, 200 Elizabeth Street, 12 EN 212, Toronto, Ontario, Canada M5G 2C4
    Support Care Cancer 20:641-5. 2012
    ..We explored regret in thyroid cancer patients, relating to the decision to accept or reject adjuvant radioactive iodine treatment...
  13. ncbi request reprint Circulating IGF-I levels in monitoring and predicting efficacy during long-term GH treatment of GH-deficient adults
    S Ezzat
    Division of Endocrinology and Metabolism, University of Toronto, Canada
    Eur J Endocrinol 149:499-509. 2003
    ..To investigate the effects of long-term GH in GH-deficient adults, as predicted by IGF-I levels...
  14. ncbi request reprint The MEN-1 gene is rarely down-regulated in pituitary adenomas
    S L Asa
    Department of Pathology, Mount Sinai Hospital, University of Toronto, Ontario, Canada
    J Clin Endocrinol Metab 83:3210-2. 1998
    ....
  15. ncbi request reprint The endogenous fibroblast growth factor-2 antisense gene product regulates pituitary cell growth and hormone production
    S L Asa
    Department of Pathology and Laboratory Medicine, Mount Sinai Hospital, Toronto, Ontario, Canada M5G 2M9
    Mol Endocrinol 15:589-99. 2001
    ..GFG represents a novel mechanism involved in restraining pituitary tumor cell growth while promoting hormonal activity...
  16. pmc Evidence for growth hormone (GH) autoregulation in pituitary somatotrophs in GH antagonist-transgenic mice and GH receptor-deficient mice
    S L Asa
    Department of Pathology and Laboratory Medicine, Mount Sinai Hospital, University of Toronto, Toronto, Ontario, Canada
    Am J Pathol 156:1009-15. 2000
    ..This represents the first evidence of direct GH feedback inhibition on pituitary somatotrophs, which may have implications for the use of GH analogs in different clinical settings...
  17. doi request reprint The insulin resistance Grb14 adaptor protein promotes thyroid cancer ret signaling and progression
    K Balogh
    Department of Medicine, University Health Network, Toronto, Ontario, Canada
    Oncogene 31:4012-21. 2012
    ..Our findings uncover a new role for Grb14 in finely tuning receptor signaling and modulating thyroid cancer progression...
  18. ncbi request reprint Immunohistochemical diagnosis of papillary thyroid carcinoma
    C C Cheung
    Department of Pathology Medicine, The Freeman Center in Endocrine Onology, Mount Sinai Hospital, University of Toronto, Toronto Canada
    Mod Pathol 14:338-42. 2001
    ..HBME-1 positivity indicates malignancy but not papillary differentiation. Only rarely are all three markers negative in PC; this panel therefore provides an objective and reproducible tool for the analysis of difficult thyroid nodules...
  19. ncbi request reprint The spectrum and significance of primary hypophysitis
    C C Cheung
    The Freeman Center for Endocrine Oncology, Mount Sinai Hospital, Department of Pathology, University of Toronto, Toronto, Ontario M5G 1X5, Canada
    J Clin Endocrinol Metab 86:1048-53. 2001
    ..Histological confirmation of the diagnosis of hypophysitis can be obtained by performing a biopsy or by requesting an intraoperative frozen section consultation...
  20. ncbi request reprint Growth hormone-releasing hormone (GHRH) and GHRH receptor (GHRH-R) isoform expression in ectopic acromegaly
    N H Othman
    Department of Pathology and Laboratory Medicine, Mount Sinai Hospital, 600 University Avenue, Toronto, Ontario, Canada
    Clin Endocrinol (Oxf) 55:135-40. 2001
    ....
  21. ncbi request reprint The implication of somatotroph adenoma phenotype to somatostatin analog responsiveness in acromegaly
    Shelly Bhayana
    Department of Medicine, Mount Sinai Hospital, 600 University Avenue, Room 437, Toronto, Ontario, Canada M5G 1X5
    J Clin Endocrinol Metab 90:6290-5. 2005
    ..Persistently elevated GH and IGF-I levels are associated with increased mortality. Their response to somatostatin analogs (SSA) is variable...
  22. ncbi request reprint Analysis of ret/PTC gene rearrangements refines the fine needle aspiration diagnosis of thyroid cancer
    C C Cheung
    Department of Pathology and Laboratory Medicine, The Freeman Center for Endocrine Oncology, Mount Sinai Hospital, University of Toronto, Ontario, Canada M5G 2M9
    J Clin Endocrinol Metab 86:2187-90. 2001
    ..The results indicate that RT-PCR for ret/PTC is a specific marker that can be applied to fine needle aspiration biopsies and improves the diagnosis of malignancy when used as an adjunct to traditional cytology...
  23. ncbi request reprint Distinct clonal composition of primary and metastatic adrencorticotrophic hormone-producing pituitary carcinoma
    A Zahedi
    Department of Medicine, The University of Toronto, Toronto, Ontario, Canada
    Clin Endocrinol (Oxf) 55:549-56. 2001
    ..This is the first description of a metastatic pituitary carcinoma with a distinct clonal composition from its primary source...
  24. ncbi request reprint CEACAM1 impedes thyroid cancer growth but promotes invasiveness: a putative mechanism for early metastases
    W Liu
    Department of Pathology, University Health Network and Toronto Medical Laboratories, and University Hospital Hamburg Eppendorf, Ontario, Canada
    Oncogene 26:2747-58. 2007
    ..Our data highlight a complex repertoire of actions providing a putative mechanism underlying the spectrum of biologic behaviors associated with thyroid cancer...
  25. ncbi request reprint Acromegaly
    S Ezzat
    University of Toronto, Wellesley Hospital, Ontario, Canada
    Endocrinol Metab Clin North Am 26:703-23. 1997
    ..This article reviews recent advances in our understanding of acromegaly and the impact of current approaches on the diagnosis and monitoring of patients with this disorder...
  26. ncbi request reprint The influence of growth hormone status on physical impairments, functional limitations, and health-related quality of life in adults
    Linda J Woodhouse
    School of Rehabilitation Science, McMaster University, Hamilton, Ontario, Canada
    Endocr Rev 27:287-317. 2006
    ....
  27. ncbi request reprint AIP Mutations are not identified in patients with sporadic pituitary adenomas
    Rebecca Digiovanni
    Department of Pathology, University Health Network and Toronto Medical Laboratories, Ontario Cancer Institute, Toronto, Ontario, Canada
    Endocr Pathol 18:76-8. 2007
    ..Our results indicate that mutations in AIP are not identified in sporadic pituitary adenomas of Canadian patients. This rare mechanism of pituitary tumorigenesis appears to be unique to the initial Finnish and Italian families described...
  28. ncbi request reprint Clinical predictors of advanced sellar masses
    Gloria M Rambaldini
    Department of Medicine, York Central Hospital, Richmond Hill, Ontario, Canada
    Endocr Pract 13:609-14. 2007
    ..To identify clinical variables associated with the presence of a structurally advanced sellar mass (ASM)...
  29. ncbi request reprint Ventilation threshold as a measure of impaired physical performance in adults with growth hormone excess
    Scott G Thomas
    Departments of Physical Therapy and Medicine, The University of Toronto, Toronto, Ontario, Canada
    Clin Endocrinol (Oxf) 56:351-8. 2002
    ..We investigated whether submaximal measures of aerobic performance can be used to assess GH excess-associated fatigue objectively...
  30. pmc How can we meet the information needs of patients with early stage papillary thyroid cancer considering radioactive iodine remnant ablation?
    A M Sawka
    Division of Endocrinology, Department of Medicine, University Health Network, University of Toronto, 200 Elizabeth Street, Toronto, Ontario, Canada
    Clin Endocrinol (Oxf) 74:419-23. 2011
    ..In the future, DAs may play an expanded role as an adjunct to physician counselling in the care of patients with thyroid cancer...
  31. ncbi request reprint Does normalization of prolactin levels result in weight loss in patients with prolactin secreting pituitary adenomas?
    R Yermus
    Mount Sinai Hospital, Toronto, Ontario, Canada
    Clin Endocrinol (Oxf) 56:562. 2002
  32. ncbi request reprint Gender-specific responses of lean body composition and non-gender-specific cardiac function improvement after GH replacement in GH-deficient adults
    S Ezzat
    Division of Endocrinology and Metabolism, University of Toronto, Toronto, Ontario, Canada M5G 2C4
    J Clin Endocrinol Metab 87:2725-33. 2002
    ..In contrast, cardiac function improvement appears to benefit both genders equally...
  33. ncbi request reprint Granulomatous hypophysitis with psammoma bodies: a diagnostic dilemma
    R Jastania
    Department of Laboratory Medicine and Pathobiology, University of Toronto, University Health Network and Toronto Medical Laboratories, Canada
    Endocr Pathol 15:359-63. 2004
    ..This finding has not previously been described in the literature. The diagnostic implications of this finding are complex, and the pathogenesis of psammoma body formation in this idiopathic disorder remains unknown...
  34. ncbi request reprint The transcription activator steroidogenic factor-1 is preferentially expressed in the human pituitary gonadotroph
    S L Asa
    Department of Pathology, Mount Sinai Hospital, Toronto, Ontario, Canada
    J Clin Endocrinol Metab 81:2165-70. 1996
    ..We conclude that SF-1 expression correlates with the expression of gonadotropins. These findings implicate SF-1 as a cell-specific transcription factor that may regulate gonadotroph differentiation in the pituitary...
  35. ncbi request reprint Myostatin is a skeletal muscle target of growth hormone anabolic action
    Wei Liu
    Department of Medicine, Mount Sinai Hospital and University of Toronto, Ontario, Canada
    J Clin Endocrinol Metab 88:5490-6. 2003
    ..Conversely, GH receptor antagonism resulted in up-regulation of myostatin in myoblasts. Given the potent catabolic actions of myostatin, our data suggest that myostatin represents a potential key target for GH-induced anabolism...
  36. ncbi request reprint Dopaminergic resistant prolactinomas in the peripubertal population
    Carol Huang
    Department of Pediatrics, Division of Endocrinology, Hospital for Sick Children and University of Toronto, Ontario, Canada
    J Pediatr Endocrinol Metab 19:951-3. 2006
    ..Both required surgical debulking, and one has received growth hormone treatment with no increase in tumor size...
  37. ncbi request reprint Acromegaly: re-thinking the cancer risk
    Siobhan Loeper
    Department of Medicine, University of Toronto, Toronto, Ontario, Canada
    Rev Endocr Metab Disord 9:41-58. 2008
    ..Instead, we explore the hypothesis that acromegaly, independent of hormone secretion, is a disease that heralds genetic and/or epigenetic alterations predisposing to cancer risk elsewhere...
  38. ncbi request reprint Medical management of pituitary adenomas: structural and ultrastructural changes
    Sylvia L Asa
    Department of Laboratory Medicine and Pathobiology, University of Toronto, University Health Network and Toronto Medical Laboratories, Ontario, Canada
    Pituitary 5:133-9. 2002
    ..In some cases, these morphologic alterations can evoke diagnostic problems...
  39. ncbi request reprint Genetics and proteomics of pituitary tumors
    Sylvia L Asa
    Endocrine Oncology Site Group, Mount Sinai and Princess Margaret Hospitals, University of Toronto, Toronto, Ontario, Canada
    Endocrine 28:43-7. 2005
    ..The underlying mechanisms for dysregulated cell adhesive molecules including cadherins and FGFRs are reviewed. The combined use of genetic and proteomic approaches will enhance novel drug therapeutic development...
  40. pmc An essential role for the hematopoietic transcription factor Ikaros in hypothalamic-pituitary-mediated somatic growth
    Shereen Ezzat
    Department of Medicine, Mount Sinai Hospital, University of Toronto, 610 University Avenue, Toronto, ON, Canada M5G 2M9
    Proc Natl Acad Sci U S A 103:2214-9. 2006
    ..These findings unmask a wider role for Ikaros in the neuroendocrine system, highlighting a critical contribution to the development of the hypothalamic-pituitary somatotrophic axis...
  41. doi request reprint The pathogenesis of pituitary tumors
    Sylvia L Asa
    Department of Laboratory Medicine and Pathobiology, University of Toronto, University Health Network and Ontario Cancer Institute, Toronto, Ontario, Canada
    Annu Rev Pathol 4:97-126. 2009
    ....
  42. ncbi request reprint Targeting N-cadherin through fibroblast growth factor receptor-4: distinct pathogenetic and therapeutic implications
    Shereen Ezzat
    Department of Medicine, University of Toronto, Toronto, Ontario, Canada
    Mol Endocrinol 20:2965-75. 2006
    ..These data highlight the pathogenetic significance of N-cadherin misexpression and emphasize the importance of FGFR partnership in mediating its functions...
  43. ncbi request reprint Mechanisms of disease: The pathogenesis of pituitary tumors
    Shereen Ezzat
    The Freeman Centre for Endocrine Oncology, Mount Sinai Hospital, Toronto, Ontario, Canada
    Nat Clin Pract Endocrinol Metab 2:220-30. 2006
    ..Mouse models have validated the roles of these alterations, which can be targets for the development of therapies that can manage these lesions. These therapies are increasingly recognized as critical for quality of life...
  44. ncbi request reprint Basis for physician recommendations for adjuvant radioiodine therapy in early-stage thyroid carcinoma: principal findings of the Canadian-American thyroid cancer survey
    Anna M Sawka
    Division of Endocrinology, Department of Medicine, University Health Network, Toronto, Ontario, Canada
    Endocr Pract 14:175-84. 2008
    ....
  45. ncbi request reprint A growth hormone receptor mutation impairs growth hormone autofeedback signaling in pituitary tumors
    Sylvia L Asa
    Department of Pathology, University Health Network and Toronto Medical Laboratories, Mount Sinai Hospital, Ontario Cancer Institute, Toronto, Ontario, Canada
    Cancer Res 67:7505-11. 2007
    ....
  46. ncbi request reprint Anabolic growth hormone action improves submaximal measures of physical performance in patients with HIV-associated wasting
    John G Esposito
    Graduate Department of Rehabilitation Science, Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada
    Am J Physiol Endocrinol Metab 289:E494-503. 2005
    ..62, P = 0.024). We concluded that GH treatment-induced LBM gains in HIV-associated wasting were functionally relevant, as determined by effort-independent submaximal measures of cardiopulmonary exercise testing...
  47. ncbi request reprint The pathogenesis of pituitary tumours
    Sylvia L Asa
    Department of Pathology and Laboratory Medicine, University of Toronto, University Health Network and Toronto Medical Laboratories, 610 University Avenue, Toronto, Ontario, Canada M5G 2M5
    Nat Rev Cancer 2:836-49. 2002
  48. ncbi request reprint Growth hormone treatment improves peripheral muscle oxygen extraction-utilization during exercise in patients with human immunodeficiency virus-associated wasting: a randomized controlled trial
    John G Esposito
    Graduate Department of Rehabilitation Science, Faculty of Medicine, University of Toronto, Ontario, Canada M5G 1X5
    J Clin Endocrinol Metab 89:5124-31. 2004
    ..Therefore, treatment with rhGH leads to an improvement in peripheral muscle oxygen extraction-utilization and the Q-VO(2) relationship during exercise in patients with HIV-associated wasting despite antiretroviral therapy...
  49. ncbi request reprint Exercise training benefits growth hormone (GH)-deficient adults in the absence or presence of GH treatment
    Scott G Thomas
    Faculty of Physical Education and Health and Faculty of Medicine, The University of Toronto, Toronto, Ontario M5S 2W6, Canada
    J Clin Endocrinol Metab 88:5734-8. 2003
    ..The beneficial effects of exercise can mimic and are not additive to the effects of GH treatment alone...
  50. ncbi request reprint IGF-I and testosterone levels as predictors of bone mineral density in healthy, community-dwelling men
    Diana Rucker
    Department of Medicine, University of Calgary, Calgary, Alberta, Canada
    Clin Endocrinol (Oxf) 60:491-9. 2004
    ..In this cross-sectional study, the relation between serum IGF-I and gonadal hormones with bone mineral density (BMD) was examined in community-dwelling men...
  51. pmc Ikaros isoforms in human pituitary tumors: distinct localization, histone acetylation, and activation of the 5' fibroblast growth factor receptor-4 promoter
    Shereen Ezzat
    Department of Medicine, Mount Sinai Hospital, University Health Network, University of Toronto, 610 University Avenue, 4 302, Toronto, Ontario, Canada M5G 2M9
    Am J Pathol 163:1177-84. 2003
    ..We conclude that dominant-negative Ik6 isoforms with their distinct localization and effects on Ik1 action may contribute to the altered expression of FGFR4 and possibly other target genes in human pituitary tumors...
  52. ncbi request reprint Vitamin D and its analog EB1089 induce p27 accumulation and diminish association of p27 with Skp2 independent of PTEN in pituitary corticotroph cells
    Wei Liu
    Department of Medicine, Mount Sinai Hospital, Toronto, Ontario, Canada
    Brain Pathol 12:412-9. 2002
    ..Our findings highlight p27 and VD analogs as targets for manipulation and drug development respectively in the treatment of inoperable corticotroph adenomas...
  53. ncbi request reprint Complex endocrinopathies in MEN-1: diagnostic dilemmas in endocrine oncology
    Nabeel Y Y Al Brahim
    Department of Pathology, University Health Network, 200 Elizabeth Street, 11th Floor, Toronto, Ontario M5G 2C4, Canada
    Endocr Pathol 18:37-41. 2007
    ....
  54. pmc Epigenetic silencing through DNA and histone methylation of fibroblast growth factor receptor 2 in neoplastic pituitary cells
    Xuegong Zhu
    Department of Medicine, Mount Sinai Hospital and University of Toronto, Canada
    Am J Pathol 170:1618-28. 2007
    ..These data highlight the contribution from DNA and histone methylation as epigenetic mechanisms responsible for FGFR2 silencing in pituitary neoplasia...
  55. ncbi request reprint Pseudopheochromocytoma of pregnancy
    Baiju R Shah
    Department of Medicine, University of Toronto, Ontario, Canada
    Endocr Pract 9:376-9. 2003
    ..To report a diagnostically challenging case of preeclampsia...
  56. ncbi request reprint Pituitary tumor AP-2alpha recognizes a cryptic promoter in intron 4 of fibroblast growth factor receptor 4
    ShunJiang Yu
    Department of Medicine, Mount Sinai Hospital, Toronto, Ontario M5G 2M9, Canada
    J Biol Chem 278:19597-602. 2003
    ..AP-2alpha and chromatin changes may contribute to the utilization of an alternative transcription start site leading to the genesis of the tumorigenic ptd-FGFR4 isoform...
  57. ncbi request reprint Regional differences in opinions on adjuvant radioactive iodine treatment of thyroid carcinoma within Canada and the United States
    Anna M Sawka
    Division of Endocrinology and Department of Medicine, University Health Network Toronto, Ontario, Canada
    Thyroid 17:1235-42. 2007
    ..To identify regional differences in recommendations for radioactive iodine remnant ablation (RRA) in early stage well-differentiated thyroid carcinoma (WDTC) within Canada and the United States...
  58. ncbi request reprint Circulating and synovial levels of IGF-I, cytokines, physical function and anthropometry differ in women awaiting total knee arthroplasty when compared to men
    Sonia M C Pagura
    Centre for Studies of Physical Function, Orthopaedic and Arthritic Institute, 43 Wellesley Street East, Toronto, Ontario, Canada M4Y 1H1
    J Orthop Res 23:397-405. 2005
    ..Determine if gender differences in osteoarthritis relate to cytokine and growth factor levels...
  59. doi request reprint A systematic review examining the effects of therapeutic radioactive iodine on ovarian function and future pregnancy in female thyroid cancer survivors
    Anna M Sawka
    Division of Endocrinology, Department of Medicine, University Health Network Toronto, Ontario, Canada
    Clin Endocrinol (Oxf) 69:479-90. 2008
    ..For women with differentiated thyroid carcinoma (DTC), the effect of radioactive iodine (RAI) therapy on gonadal and reproductive function is an important consideration...
  60. doi request reprint Fibroblast growth factor 2 and estrogen control the balance of histone 3 modifications targeting MAGE-A3 in pituitary neoplasia
    Xuegong Zhu
    Department of Medicine, University of Toronto, Toronto, Ontario, Canada
    Clin Cancer Res 14:1984-96. 2008
    ..cDNA profiling identified the cancer-testis antigen melanoma-associated antigen A3 (MAGE-A3) as a putative target negatively regulated by FGFR2...
  61. ncbi request reprint Epigenetic control in pituitary tumors
    Shereen Ezzat
    Department of Medicine, University of Toronto, Toronto, Ontario, Canada
    Endocr J 55:951-7. 2008
    ..The pathogenetic and potential therapeutic implications are discussed...
  62. ncbi request reprint Fibroblast growth factor receptor 4 is a target for the zinc-finger transcription factor Ikaros in the pituitary
    ShunJiang Yu
    Department of Medicine, Mount Sinai Hospital and University of Toronto, Toronto, Ontario, Canada M5G 2M9
    Mol Endocrinol 16:1069-78. 2002
    ..Our findings point to a new role for Ik outside the hematopoietic system and suggest a novel transcriptional contribution with Ets and Sp1 in regulation of FGFR4 in the pituitary...
  63. pmc Targeted expression of a human pituitary tumor-derived isoform of FGF receptor-4 recapitulates pituitary tumorigenesis
    Shereen Ezzat
    Department of Medicine, University of Toronto, Toronto, Ontario, Canada
    J Clin Invest 109:69-78. 2002
    ..Here we show that targeted expression of ptd-FGFR4, but not FGFR4, results in pituitary tumors that morphologically recapitulate the human disease...
  64. ncbi request reprint Controversies in papillary microcarcinoma of the thyroid
    Monique Piersanti
    Department of Medicine, Mount Sinai Hospital and University of Toronto, Toronto, Ontario, Canada M5G 2M9
    Endocr Pathol 14:183-91. 2003
    ..Review of the literature substantiates the argument that clinically evident PTC may be distinctly different from solitary or multifocal PMC in terms of etiology and biologic behavior, supporting a conservative approach to management...
  65. ncbi request reprint The zinc finger Ikaros transcription factor regulates pituitary growth hormone and prolactin gene expression through distinct effects on chromatin accessibility
    Shereen Ezzat
    Department of Medicine, Mount Sinai Hospital and University of Toronto, Ontario, Canada
    Mol Endocrinol 19:1004-11. 2005
    ..These data provide evidence for Ikaros-mediated histone acetylation and chromatin remodeling in the selective regulation of pituitary GH and PRL hormone gene expression...
  66. ncbi request reprint Comparison of body composition assessment methods in patients with human immunodeficiency virus-associated wasting receiving growth hormone
    John G Esposito
    Graduate Department of Rehabilitation Science, University of Toronto, Toronto, Ontario, Canada M5G 1V7
    J Clin Endocrinol Metab 91:2952-9. 2006
    ....
  67. ncbi request reprint Cytoplasmic expression of fibroblast growth factor receptor-4 in human pituitary adenomas: relation to tumor type, size, proliferation, and invasiveness
    Zhi Rong Qian
    Department of Pathology, University of Tokushima School of Medicine, Tokushima, Japan
    J Clin Endocrinol Metab 89:1904-11. 2004
    ..Moreover, detection of FGFR4 cytoplasmic staining may provide an ancillary diagnostic tool in the diagnosis of pituitary adenoma, particularly in equivocal cases...
  68. ncbi request reprint The cost of medical care for the acromegalic patient
    Robert Knutzen
    Pituitary Network Association, Thousand Oaks, Calif 91358, USA
    Neuroendocrinology 83:139-44. 2006
    ..We anticipate that such measures will serve to limit the psychological, emotional and economic burden of this potentially debilitating disease...
  69. ncbi request reprint Dual inhibition of RET and FGFR4 restrains medullary thyroid cancer cell growth
    Shereen Ezzat
    Department of Medicine, Mount Sinai Hospital and University of Toronto, Toronto, Ontario, Canada
    Clin Cancer Res 11:1336-41. 2005
    ..These data highlight RET and FGFR4 as therapeutic targets and suggest a potential role for the combined use of tyrosine kinase inhibitors in the management of inoperable medullary thyroid cancers...
  70. ncbi request reprint Short-term safety and efficacy of human GH replacement therapy in 595 adults with GH deficiency: a comparison of two dosage algorithms
    Anne Kehely
    Lilly Research Centre, Erl Wood Manor, Windlesham, Surrey GU20 6PH, United Kingdom
    J Clin Endocrinol Metab 87:1974-9. 2002
    ..The lower starting dose with dose titration appeared more favorable, but differences in response between genders and onset of GH deficiency need to be taken into account when setting an individual dose regimen...
  71. pmc Vitamin D arrests thyroid carcinoma cell growth and induces p27 dephosphorylation and accumulation through PTEN/akt-dependent and -independent pathways
    Wei Liu
    Department of Medicine, Mount Sinai Hospital, Toronto, Ontario, Canada
    Am J Pathol 160:511-9. 2002
    ..These properties support the potential utility of VD analogs in the treatment of thyroid carcinomas irrespective of their PTEN/pAkt status...
  72. ncbi request reprint Fibroblast growth factor receptor 4 (FGFR4) mediates signaling to the prolactin but not the FGFR4 promoter
    ShunJiang Yu
    Department of Medicine, Mount Sinai Hospital and University of Toronto, Toronto, Ontario, Canada
    Am J Physiol Endocrinol Metab 283:E490-5. 2002
    ..We conclude that FGFR4 mediates FGF-19 signaling to the PRL promoter. Our data also suggest a possible functional role for Ik in sorting Ets signals to the FGFR4 promoter, as distinct from the PRL promoter, where Ets partners with Pit1...
  73. ncbi request reprint 1alpha,25-Dihydroxyvitamin D3 targets PTEN-dependent fibronectin expression to restore thyroid cancer cell adhesiveness
    Wei Liu
    Department of Pathology, University Health Network and Toronto Medical Laboratories, University of Toronto, 610 University Avenue, Suite 4 302, Toronto, Ontario, Canada M5G 2M9
    Mol Endocrinol 19:2349-57. 2005
    ..Taken together, our findings highlight the significance of FN in modulating thyroid cancer cell adhesiveness and, at least in part, in mediating VD actions on neoplastic cell growth...
  74. doi request reprint Inhibition of the sodium/potassium ATPase impairs N-glycan expression and function
    Reza Beheshti Zavareh
    Ontario Cancer Institute, Princess Margaret Hospital, Canada
    Cancer Res 68:6688-97. 2008
    ..These molecules can be used as tools to better understand the role of N-glycans in normal and malignant cells. Moreover, these results may partly explain the anticancer effect of CGs in cardiovascular patients...
  75. ncbi request reprint Growth factors and their receptors in the genesis and treatment of thyroid cancer
    Shereen Ezzat
    Department of Medicine, University of Toronto, Ontario, Canada M5G 1X5
    Cancer Treat Res 122:121-9. 2004
  76. ncbi request reprint Fibroblast growth factor receptors as molecular targets in thyroid carcinoma
    Rosanne St Bernard
    Department of Pathology, University Health Network and University of Toronto, Toronto, Ontario, Canada
    Endocrinology 146:1145-53. 2005
    ..These data indicate a role for FGFR-4 in human thyroid cancer cell progression and provide a rationale for FGFR manipulation as a potentially novel therapeutic approach...
  77. ncbi request reprint Sp1-mediated transcriptional control of fibroblast growth factor receptor 4 in sarcomas of skeletal muscle lineage
    Shun Jiang Yu
    Department of Medicine, Mount Sinai Hospital and University of Toronto, The Freeman Centre for Endocrine Oncology and The Ontario Cancer Institute, Toronto, Ontario, Canada
    Clin Cancer Res 10:6750-8. 2004
    ..Our findings point to Sp1 as an important contributor to FGFR4 transcriptional control and elucidate a potential mechanism for the heterogeneous expression of FGFR4 in neoplasms derived from the same cell lineage...
  78. doi request reprint Dexamethasone increases ubiquitin transcription through an SP-1 dependent mechanism in multiple myeloma cells
    Xinliang Mao
    Leuk Res 32:1480-2. 2008
  79. ncbi request reprint Distinct transcriptional control and action of fibroblast growth factor receptor 4 in differentiating skeletal muscle cells
    ShunJiang Yu
    Department of Medicine, Mount Sinai Hospital and University of Toronto, The Freeman Centre for Endocrine Oncology and The Ontario Cancer Institute, Toronto, Ontario, Canada
    Lab Invest 84:1571-80. 2004
    ..This significantly impeded Erk1/2 phosphorylation and differentiation of myoblasts into MHC-expressing myotubes. Our findings point to distinct transcriptional regulation and action for FGFR4 in differentiating skeletal muscle cells...
  80. ncbi request reprint Canadian guidelines for the management of adult growth hormone deficiency
    Ehud Ur
    Division of Endocrinology, QEII Health Sciences Centre, Dalhousie University, Halifax, Nova Scotia
    Clin Invest Med 29:83-90. 2006
    ..To develop guidelines for the management of growth hormone (GH) deficiency in Canadian adults to facilitate rational use of GH in appropriate indications...
  81. ncbi request reprint The cancer/testis antigen melanoma-associated antigen-A3/A6 is a novel target of fibroblast growth factor receptor 2-IIIb through histone H3 modifications in thyroid cancer
    Tetsuo Kondo
    Department of Pathology, Princess Margaret Hospital, University Health Network, University of Toronto, Toronto, Ontario, Canada
    Clin Cancer Res 13:4713-20. 2007
    ..In this analysis, we examined a novel target of FGFR2-IIIb signaling, melanoma-associated antigen-A3 and A6 (MAGE-A3/6)...
  82. pmc Diagnosis and management of hyperprolactinemia
    Omar Serri
    Division of Endocrinology, University of Montreal, Montreal, Que
    CMAJ 169:575-81. 2003
    ....
  83. ncbi request reprint Tumor-derived Ikaros 6 acetylates the Bcl-XL promoter to up-regulate a survival signal in pituitary cells
    Shereen Ezzat
    Department of Medicine, Mount Sinai Hospital and University of Toronto, Toronto, Ontario, Canada
    Mol Endocrinol 20:2976-86. 2006
    ..Thus, the contribution of Ik6 to tumor pathogenesis involves up-regulation of an antiapoptotic signal generated through selective acetylation of the Bcl-XL promoter...
  84. ncbi request reprint Pituitary tumor pathogenesis--the hunt for novel candidate genes continues
    Shereen Ezzat
    J Clin Endocrinol Metab 88:5116-8. 2003
  85. ncbi request reprint Microadenomatosis of the pancreas in von Hippel-Lindau disease
    Runjan Chetty
    Am J Surg Pathol 30:1630; author reply 1630-1. 2006